Rigel Announces Third Quarter 2009 Financi...(and the timing thereof and Rigel's abili...),Health

Date:11/3/2009

and the timing thereof and Rigel's ability to enter into a corporate collaboration agreement with respect to R788 on the anticipated timing, or at all. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "expect," plan," will," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success of clinical trials and the commercialization of product candidates, potential problems that may arise in the research and development and approval process and risks associated with Rigel's ability to enter into a collaboration agreement with respect to R788 and reliance on a corporate partner, as well as other risks detailed from time to time in Rigel's filings with the SEC, including under the heading "Risk Factors" in the prospectus supplement related to Rigel's recent public offering filed with the Securities and Exchange Commission on September 17, 2009. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

    Contact: Ryan D. Maynard
    Phone: 650.624.1284
    Email: invrel@rigel.com

    Contact: Raul R. Rodriguez
    Phone: 650.624.1302
    Email: invrel@rigel.com



                               STATEMENTS OF OPERATIONS
                       (in thous
'/>"/>
SOURCE  Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 
Related medicine technology :

1. Rigel Announces Presentations at Two Investor Conferences
2. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
3. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
4. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
9. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
10. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
11. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders